ALL POSTS BY: Ethel Purdy

Ethel Purdy – Medical Blogger & Pharmacist
Bridging the world of wellness and science, Ethel Purdy is a professional voice in healthcare with a passion for sharing knowledge. At 36, she stands at the confluence of medical expertise and the written word, holding a pharmacy degree acquired under the rigorous education systems of Germany and Estonia.
Her pursuit of medicine was fueled by a desire to understand the intricacies of human health and to contribute to the community's understanding of it. Transitioning seamlessly into the realm of blogging, Ethel has found a platform to demystify complex medical concepts for the everyday reader.
Ethel's commitment to the world of medicine extends beyond her professional life into a personal commitment to health and wellness. Her hobbies reflect this dedication, often involving research on the latest medical advances, participating in wellness communities, and exploring the vast and varied dimensions of health.
Join Ethel as she distills her pharmaceutical knowledge into accessible wisdom, fostering an environment where science meets lifestyle and everyone is invited to learn. Whether you're looking for insights into the latest health trends or trustworthy medical advice, Ethel’s blog is your gateway to the nexus of healthcare and daily living.

Showing: 591 - 600 of 655 RESULTS
Menarini Group and Insilico Medicine enter into exclusive global license agreement for new KAT6 inhibitor for potential treatment of breast cancer and other oncology indications USA - Deutsch Italia - Italiano APAC - Traditional Chinese USA - español Latin America - español USA - English USA - English
Alternative Medicine

Menarini Group and Insilico Medicine enter into exclusive global license agreement for new KAT6 inhibitor for potential treatment of breast cancer and other oncology indications USA – Deutsch Italia – Italiano APAC – Traditional Chinese USA – español Latin America – español USA – English USA – English

KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with …